REF: Clinical Trial Planning, Design, Execution

1. Considerations for the Design of Early-Phase Clinical Trials of Cellular and Gene Therapy Products; Guidance for Industry. (2015, June). Retrieved from Food and Drug Administration: https://www.fda.gov/media/106369/download
2. Rare-disease researchers pioneer a unique approach to clinical trials. (2023, May 5). Retrieved from Nature Medicine: https://www.nature.com/articles/s41591-023-02333-4

Demonstration of direct benefit in pediatrics for sponsors in early engagements with the FDA 

1. 21 CFR 50 Subpart D 50.52
2. Human Gene Therapy for Rare Diseases, Guidance for Industry, January 2020
3. Nonclinical Safety Evaluation of Pediatric Drug Products, Guidance for Industry, February 2006
4. The present and future of gene therapy in pediatrics, Children’s National, May 2025
5. Rare Pediatric Disease Designation and Priority Review Voucher Programs, September 2024

Bioanalytical testing 

1. FDA Guidance for Industry: Bioanalytical Method Validation, May 2018 
2. FDA Guidance for Industry: Human Gene Therapy for Rare Disease, January 2020 
3. BGTC Bioanalytical Strategy, June 2025 
4. FDA Guidance for Industry: Preclinical Assessment of Investigational Cellular and Gene Therapy Products, November 2013 
5. FDA Guidance for Industry: Design and Analysis of Shedding Studies for Virus or Bacteria-Based Gene Therapy and Oncolytic Products, August 2015 
6. Chemistry, Manufacturing & Control Information for Human Gene Therapy Investigational New Drug Applications Guidance for Industry 1/2020 
7. Potency Test for Cellular and Gene Therapy Products 1/2011 
8. Intracellular Cytokine Staining 
9. qPCR and qRT-PCR analysis

Analysis of endpoints and statistical approach

1. U.S. Food and Drug Administration. Rare Diseases: Considerations for the Development of Drugs and Biological Products. U.S. Department of Health and Human Services, Dec. 2023, https://www.fda.gov/regulatory-information/search-fda-guidance-documents/rare-diseases-considerations-development-drugs-and-biological-products
2. U.S. Food and Drug Administration. Interacting with the FDA on Complex Innovative Trial Designs for Drugs and Biological Products: Guidance for Industry. U.S. Department of Health and Human Services, Dec. 2020, https://www.fda.gov/media/130897/download
3. U.S. Food and Drug Administration. Multiple Endpoints in Clinical Trials: Guidance for Industry. U.S. Department of Health and Human Services, Oct. 2022, https://www.fda.gov/media/162416/download
4. FDA–NIH Biomarker Working Group. BEST (Biomarkers, Endpoints, and Other Tools) Resource. U.S. Food and Drug Administration and National Institutes of Health, 2016–, National Center for Biotechnology Information, https://www.ncbi.nlm.nih.gov/books/NBK338448/
5. U.S. Food and Drug Administration. Human Gene Therapy for Rare Diseases: Guidance for Industry. U.S. Department of Health and Human Services, Jan. 2020, https://www.fda.gov/media/113807/download
6. U.S. Food and Drug Administration. Rare Diseases: Considerations for the Development of Drugs and Biological Products. U.S. Department of Health and Human Services, Dec. 2023, Rare Diseases: Considerations for the Development of Drugs and Biological Products
7. U.S. Food and Drug Administration. Focus Area: Patient-Reported Outcomes and Other Clinical Outcome Assessments. U.S. Department of Health and Human Services, https://www.fda.gov/science-research/focus-areas-regulatory-science-report/focus-area-patient-reported-outcomes-and-other-clinical-outcome-assessments
8. U.S. Food and Drug Administration. Use of Bayesian Methodology in the Design and Analysis of Clinical Trials for Drug and Biological Products: Draft Guidance for Industry. U.S. Department of Health and Human Services, Jan. 2026, Use of Bayesian Methodology in the Design and Analysis of Clinical Trials for Drug and Biological Products

Overview of clinical, medical, and data monitoring

1. A Risk-Based Approach to Monitoring of Clinical Investigations Questions and Answers: Guidance for Industry, FDA (April 2023)
2. Oversight of Clinical Investigations – A Risk-Based Approach to Monitoring: Guidance for Industry, FDA (August 2013)
3. E6(R2) Good Clinical Practice: Integrated Addendum to ICH E6(R1)
4. 21 CFR 312 Subpart D – Responsibilities of Sponsors and Investigators
5. ICH, Integrated Addendum to ICH E6(R1): Guideline for Good Clinical Practice (E6(R2))
6. Long Term Follow-Up After Administration of Human Gene Therapy Products, FDA (January 2020)
7. Monitoring of Clinical Trials, ICH GCP Network
8. Use of Data Monitoring Committees in Clinical Trials, FDA (February 2024)